CF
MRNA icon

Cantor Fitzgerald’s Moderna MRNA Stock Holding History

Cantor Fitzgerald’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25,000
Closed -$541K – 271
2024
Q2 		$541K Buy
+25,000
New +$3.16M 0.11% 102

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cantor Fitzgerald's MRNA Position: Q1 2026 in Review

Cantor Fitzgerald opened a new position in Moderna (MRNA) in Q1 2026: 10,009 shares worth $508K. The stake represents 0.01% of the portfolio and ranks #216 among its holdings. This is a return to the name: Cantor Fitzgerald previously reported a position in MRNA as recently as Q3 2025.

Cantor Fitzgerald first reported a position in MRNA in Q2 2022 and has held it in 11 quarters since. The position peaked at $4.34M in Q2 2022. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Cantor Fitzgerald held 10,009 shares of Moderna worth $508K as of Q1 2026.
  • Moderna was a new Cantor Fitzgerald position in Q1 2026.
  • Moderna made up 0.01% of Cantor Fitzgerald's portfolio in Q1 2026, its #216 holding.
  • Cantor Fitzgerald first reported a position in Moderna in Q2 2022 and has held it in 11 quarters since.
  • Cantor Fitzgerald's Moderna position peaked at $4.34M in Q2 2022.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Cantor Fitzgerald's 13F filing for Q1 2026, filed 15 May 2026.